Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

BAP1, PBRM1, and metabolic pathway changes correlate with RCC subtype-specific survival

Ricketts C et al. Cell Reports April 2018, Pages 313–326.e5 https://doi.org/10.1016/j.celrep.2018.03.075

Key clinical point: Different histologically defined RCC subtypes are characterized by distinctive mutations, chromosomal copy number alterations, and expression patterns of mRNA, miRNA, and lncRNA. Histology plus genomics provide insight into patient-centered management. A tumor or liquid biopsy, provide invaluable information and prognostic biomarkers to guide clinical and surgical management.

Major finding: TP53 mutation correlated with decreased survival in clear cell RCC (p = 0.0002) and papillary RCC (p = 0.0049), while PTEN mutation correlated with decreased survival in chromophobe RCC (p = 0.0138). While BAP1 mutation correlated with decreased survival across the entire cohort (p = 0.0002) and within the clear cell RCC group (p = 0.0035), BAP1 mutation did not correlate with survival in papillary RCC or chromophobe RCC. Similarly, PBRM1 mutation, which has been shown to not correlate with survival in clear cell RCC, was found to correlate with decreased survival in papillary RCC (p = 0.0008) that was specific to type 1 papillary RCC (p < 0.0001).

Study details: 843 RCC from the three major histologic subtypes, including 488 clear cell RCC, 274 papillary RCC, and 81 chromophobe RCC were evaluated.

Disclosures: The authors had no relevant financial disclosures.

Source: Ricketts C et al. Cell Reports April 2018, Pages 313–326.e5 https://doi.org/10.1016/j.celrep.2018.03.075

Citation:

Ricketts C et al. Cell Reports April 2018, Pages 313–326.e5 https://doi.org/10.1016/j.celrep.2018.03.075

This Week's Must Reads

Intensity modulated radiation therapy may be preferable in children with extremity nonrhabdomyosarcoma soft-tissue sarcomas, Source: Rao A et al. Intl J Rad Oncology*Biology*Physics; Jan. 2019, 38-44. https://doi.org/10.1016/j.ijrobp.2018.09.005

TAO: Nonwhite ethnicity, limb infection predict poor prognosis, Le Joncour A et al. Arthritis Rheumatol. 2018;70(Suppl 10): Abstract 1885

Thrombolysis for acute ischemic stroke safe in GI malignancy, Inohara T et al. Circulation. 2018 Nov 6;138[suppl 1], Abstract A12291

Ten years of anastrozole boosts disease-free survival, Ohtani S et al. SABCS 2018, Abstract GS3-04

Must Reads in Renal Cell Carcinoma

Strong link found between RCC and melanoma, Kim KB et al. Cancer Epidemiol. 2018 Oct 19;57:80-4

Apo B/A1 predicts survival in metastatic renal cell carcinoma, Zhang F et al. Urol Oncol. 2018 Nov 30. doi: 10.1016/j.urolonc.2018.11.010

RCC patients with brain-only metastases may benefit from cytoreductive nephrectomy, Daugherty M et al. Urol Oncol. 2018 Dec 5.doi: 10.1016/j.urolonc.2018.10.021

Lower concentration of pazopanib linked with less toxicity, Noda S et al. Clin Genitourin Cancer. 2018 Dec 7. doi: 10.1016/j.clgc.2018.12.001

One-fourth of placebo arm experience adverse events in RCC trials, Chacón M et al. JAMA Network Open. 2018 Dec 7. doi: 10.1001/jamanetworkopen.2018.5617